#1 Clinical Trials Search in Europe

Brepocitinib Tosilate

This article explores a Phase 3 clinical trial investigating the efficacy and safety of Brepocitinib Tosilate, a new drug for treating dermatomyositis in adults. Dermatomyositis is a rare autoimmune condition affecting the skin and muscles. The study aims to evaluate how well Brepocitinib works compared to a placebo over 52 weeks of daily treatment, focusing on improvements in disease activity, disability, and skin symptoms.

Table of Contents

What is Brepocitinib?

Brepocitinib, also known by its full chemical name brepocitinib tosilate, is a promising new medication currently being studied for the treatment of dermatomyositis[1]. It is developed by Priovant Therapeutics, Inc. and is also referred to by its sponsor product code PVT-2201[1].

Target Condition: Dermatomyositis

Dermatomyositis is a rare autoimmune disease that affects both the skin and muscles. It causes skin rashes and muscle weakness, making daily activities difficult for those affected[1]. The condition can significantly impact a person’s quality of life, which is why new treatments like brepocitinib are being researched.

How Brepocitinib Works

Brepocitinib is described as a potent tyrosine kinase TYK2/JAK1 inhibitor, highly selective over other human kinases[1]. In simpler terms, this means:

  • Tyrosine kinase inhibitor: It blocks specific enzymes called tyrosine kinases, which are involved in certain cell processes.
  • TYK2/JAK1: These are specific types of tyrosine kinases that play a role in inflammation and immune responses.
  • Highly selective: It targets these specific enzymes without affecting many others, which may help reduce side effects.

By inhibiting these enzymes, brepocitinib may help reduce inflammation and modulate the immune response in people with dermatomyositis.

Ongoing Research

Brepocitinib is currently being studied in a Phase 3 clinical trial. This is an advanced stage of research that aims to confirm the drug’s effectiveness and safety[1]. The main goals of this study are:

  1. To evaluate how well brepocitinib works in treating dermatomyositis compared to a placebo (a substance with no active drug) after 52 weeks of daily use.
  2. To measure improvements using a scoring system called the Total Improvement Score (TIS), which assesses various aspects of the disease.
  3. To check if brepocitinib can help reduce the need for oral corticosteroids, which are commonly used to treat dermatomyositis but can have significant side effects with long-term use.

Eligibility Criteria for the Study

To participate in this study, patients must meet certain criteria[1]. Some key requirements include:

  • Age: 18 to 75 years old
  • Diagnosed with dermatomyositis according to specific medical criteria
  • Active muscle and skin disease
  • Current or past therapy with certain medications like corticosteroids
  • Weight between 40 kg and 130 kg, with a body mass index (BMI) less than 40 kg/m²

There are also conditions that would exclude someone from participating, such as:

  • Dermatomyositis with end-stage organ involvement or irreversible muscle damage
  • History of certain cancers or active malignancy
  • High risk of blood clots or cardiovascular disease
  • Active or recent infections

Potential Benefits of Brepocitinib

The researchers are looking at several ways brepocitinib might help patients with dermatomyositis[1]:

  • Improved overall disease activity: Measured by the Total Improvement Score (TIS)
  • Better physical function: Assessed using the Health Assessment Questionnaire (HAQ) Disability Index
  • Reduced skin symptoms: Evaluated with the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score
  • Decreased need for corticosteroids: For patients already taking these medications

Administration and Dosage

Brepocitinib is being studied as an oral medication in tablet form[1]. In the current study:

  • It is taken once daily
  • The maximum daily dose being tested is 30 mg
  • The treatment period in the study is 52 weeks (about one year)

It’s important to note that as this is still a research medication, the optimal dosage and long-term effects are still being determined.

Aspect Details
Study Type Phase 3, Randomized, Double-Blind, Placebo-Controlled
Drug Brepocitinib Tosilate (oral tablet)
Condition Dermatomyositis in adults
Primary Objective Evaluate efficacy based on Total Improvement Score (TIS) after 52 weeks
Key Secondary Objectives TIS responder rate, HAQ Disability Index, CDASI Activity Score, Corticosteroid dose reduction
Inclusion Criteria Adults 18-75 years, diagnosed dermatomyositis, active muscle and skin disease, prior treatment history
Exclusion Criteria End-stage organ involvement, irreversible muscle damage, certain cancer histories, high thrombosis risk
Treatment Duration 52 weeks
Maximum Daily Dose 30 mg
Administration Route Oral

FAQ

  • What is Brepocitinib Tosilate? Brepocitinib Tosilate is a potent tyrosine kinase TYK2/JAK1 inhibitor that is highly selective over other human kinases. It is being studied as a potential treatment for dermatomyositis, an autoimmune condition affecting the skin and muscles.
  • Who can participate in this clinical trial? The trial is open to adults aged 18 to 75 with a diagnosis of dermatomyositis, active muscle and skin disease, and a history of treatment with corticosteroids, hydroxychloroquine, or non-steroid immunosuppressants. Participants must weigh between 40 and 130 kg and have a body mass index (BMI) less than 40 kg/m².
  • What is the main goal of this clinical trial? The main goal is to evaluate the effectiveness of Brepocitinib in treating dermatomyositis. This is measured using the Total Improvement Score (TIS) after 52 weeks of daily Brepocitinib treatment compared to a placebo.
  • How is the effectiveness of Brepocitinib measured in this trial? The effectiveness is primarily measured using the Total Improvement Score (TIS), which ranges from 0 to 100. Secondary measures include the proportion of participants achieving a TIS of 40 or more points, changes in disability scores, skin symptom severity, and reductions in corticosteroid use for those taking them at the start of the trial.
  • Are there any specific exclusion criteria for this trial? Yes, participants with end-stage organ involvement, irreversible muscle damage, certain cancer histories, overlap myositis (except with Secondary Sjögren's syndrome), high risk of thrombosis or cardiovascular disease, high risk of herpes zoster reactivation, and active or recent infections are excluded from the trial.

Ongoing Clinical Trials on Brepocitinib Tosilate

  • A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Germany Hungary Italy +6

  • Study on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Germany Greece Hungary +3

Glossary

  • Dermatomyositis: A rare autoimmune disease characterized by muscle weakness and skin rash, affecting both the muscles and skin.
  • Brepocitinib Tosilate: An investigational drug that inhibits specific enzymes (TYK2 and JAK1) involved in inflammation, being studied for the treatment of dermatomyositis.
  • Total Improvement Score (TIS): A composite measure ranging from 0 to 100 that assesses improvement in dermatomyositis, based on six core measures of disease activity.
  • Placebo: An inactive substance that looks like the real medicine but contains no active ingredients, used as a control in clinical trials.
  • Phase 3 Clinical Trial: A large-scale study to confirm the effectiveness and safety of a new treatment, typically involving hundreds to thousands of participants.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • HAQ Disability Index: A measure of a person's ability to perform daily living activities, used to assess functional status in various diseases including dermatomyositis.
  • Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): A tool used to measure the extent and severity of skin symptoms in dermatomyositis.
  • Corticosteroids: A class of steroid hormones used to reduce inflammation in various conditions, including dermatomyositis.
  • Immunosuppressant: A medication that suppresses or reduces the strength of the body's immune system.
  • Tyrosine Kinase Inhibitor: A type of drug that blocks specific enzymes called tyrosine kinases, which are involved in various cellular processes including inflammation.
  • JAK1: Janus Kinase 1, an enzyme involved in the signaling of various inflammatory pathways in the body.
  • TYK2: Tyrosine Kinase 2, another enzyme involved in inflammatory signaling pathways.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy, calculated by dividing weight in kilograms by height in meters squared.
  • Randomized: A process in clinical trials where participants are assigned by chance to different treatment groups, reducing bias in the study results.
  • Double-Blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving the placebo.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-brepocitinib-for-adults-with-dermatomyositis/